annual meeting program - American Society of Clinical Oncology

Friday, June 4, 2010
Brd. 19 Cox proportional hazard analysis of sunitinib (SU) efficacy across subgroups
of patients (pts) with progressive pancreatic neuroendocrine tumors (NET).
(Abstract #4031)
E. Raymond, P. Niccoli, J. Raoul, Y. Bang, I. Borbath, C. Lombard-Bohas,
J. W. Valle, S. Patyna, R. C. Chao, D. Lu
Brd. 20 The role of octreotide imaging in detecting neuroendocrine tumors (NETs) in
2010: Do we still need it? (Abstract #4032)
L. Saltz, M. Gollub, D. L. Reidy
Brd. 21 A prospective, randomized trial of simultaneous pancreatic cancer treatment
with enoxaparin and chemotherapy: Final results of the CONKO-004 trial.
(Abstract #4033)
H. Riess, U. Pelzer, B. Opitz, M. Stauch, P. Reitzig, S. Hahnfeld, L. Müller,
J. Stieler, B. Dörken, H. Oettle
Brd. 22 ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or
bevacizumab (B) in combination with gemcitabine (G) and in combination
with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for
patients (pts) with completely resected pancreatic adenocarcinoma (PC).
(Abstract #4034)
J. Berlin, P. J. Catalano, Y. Feng, A. M. Lowy, A. W. Blackstock, P. A. Philip,
R. R. McWilliams, J. L. Abbruzzese, A. B. Benson
Brd. 23 A placebo-controlled, randomized phase II study of conatumumab (C) or
AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with
metastatic pancreatic cancer (mPC). (Abstract #4035)
H. L. Kindler, D. A. Richards, J. Stephenson, L. E. Garbo, C. S. Rocha Lima,
H. Safran, J. S. Wiezorek, E. G. Feigal, S. Bray, C. Fuchs
Brd. 24 The combination of a chemotherapy doublet (gemcitabine plus capecitabine)
with a biologic doublet (bevacizumab plus erlotinib) in patients with
advanced pancreatic adenocarcinoma: The TARGET study. (Abstract #4036)
D. J. Watkins, N. Starling, I. Chau, J. Thomas, J. Webb, J. R. Oates, G. Brown,
K. Thomas, D. Cunningham
Brd. 25 A multicenter randomized controlled trial of gemcitabine (G) alone versus
gemcitabine and S-1 combination therapy (GS) in patients with unresectable
advanced pancreatic cancer (PC): GEMSAP study. (Abstract #4037)
Y. Nakai, H. Isayama, T. Sasaki, N. Sasahira, K. Hirano, T. Tsujino, M. Tada,
M. Omata, K. Koike, GEMSAP Study Group
65
FRIDAY